A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

NCT06632860 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Iodine-resistant Thyroid Cancer
Meningioma
NETs

Interventions

DRUG: 68Ga-TATE-RGD
DRUG: 18-FDG

Sponsor

Peking Union Medical College Hospital